Aptose Biosciences Inc.
APS.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -6.58% | -12.19% | -33.93% | -24.24% | -37.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.05% | -81.97% | -40.37% | -49.18% | -30.76% |
| Operating Income | 44.05% | 81.97% | 40.37% | 49.18% | 30.76% |
| Income Before Tax | 42.50% | 86.74% | 39.26% | 48.67% | 29.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 42.50% | 86.74% | 39.26% | 48.67% | 29.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.50% | 86.74% | 39.26% | 48.67% | 29.51% |
| EBIT | 44.05% | 81.97% | 40.37% | 49.18% | 30.76% |
| EBITDA | 43.99% | 81.97% | 40.31% | 49.15% | 30.74% |
| EPS Basic | 88.16% | 97.07% | 78.74% | 80.90% | 66.88% |
| Normalized Basic EPS | 88.16% | 97.07% | 78.74% | 80.90% | 66.88% |
| EPS Diluted | 88.16% | 97.07% | 78.74% | 80.90% | 66.88% |
| Normalized Diluted EPS | 88.16% | 97.07% | 78.74% | 80.90% | 66.88% |
| Average Basic Shares Outstanding | 385.68% | 353.23% | 185.77% | 168.77% | 112.83% |
| Average Diluted Shares Outstanding | 385.68% | 353.23% | 185.77% | 168.77% | 112.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |